ArticleOpen forum infectious diseases2026
The Impact of Adopting Whole-Genome Sequencing for Tuberculosis Diagnosis in China: A Cost-Effectiveness Analysis.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: China is a high-burden tuberculosis (TB) country and delays in diagnosis and effective treatment have further exacerbated this situation. Whole-genome sequencing (WGS) has emerged as a reliable approach for drug susceptibility testing (DST) in TB. Whole-genome sequencing can not only improve TB treatment outcomes but also requires significant investments in laboratory infrastructure and trained personnel. It is unclear whether WGS is a cost-effective strategy for routine TB diagnosis in China. Methods: We developed a decision tree-Markov model to evaluate the cost-effectiveness and health impact of WGS-based DST compared with culture-based DST and rapid molecular testing strategies (Xpert and Xpert Ultra), adopting a societal perspective. Results: Base-case analysis demonstrated that WGS, Xpert, and Xpert Ultra were cost-saving strategies for TB management. Compared with culture-based DST, the incremental net monetary benefits for Xpert, Xpert Ultra, and WGS were $1750.06, $1832.84, and $1939.32, respectively. Over a lifetime horizon, WGS emerged as the optimal DST strategy, reducing direct medical costs by $401.83 per patient, gaining an additional 0.121 quality-adjusted life years per case, and decreasing TB mortality by 45 cases per 10 000 patients. Sensitivity analyses confirmed the robustness of these findings across key parameters. Conclusions: Whole-genome sequencing-based DST offers a cost-saving solution for patients with TB in China, achieving better health and economic outcomes compared with alternative strategies. The findings suggest that the widespread adoption of WGS-based DST in China would be cost-effective and aligns well with public health priorities in high-burden settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.